Treatment of Hypertension

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97 Dahlöf B, Devereux RB, Kjeldsen SV, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003 Sever PS, Dahlöf B, Poulter N, et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58 Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 Jan 30; 348(5): 383–93 Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62 Franklin S, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245–9 Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434–503 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011–53 Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA 2003; 289: 2560–71 Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressioni Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001 Sep 18; 104(12): 1385–92 O’Donnell CJ, Kannel WB. Epidemiologic appraisal of hypertension as a coronary risk factor in the elderly. Am J Geriatr Cardiol 2002 Mar-Apr; 11(2): 86–92 PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41 Yusuf S, Sleight P, Dagenais G, et al. for the Hearth Outcomes Prevention Evaluation (HOPE) Study Group. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53 Wing L, Reid CM, Ryan P, et al. for the Second Australian National Blood Pressure Study Group (ANBP2). A comparison of outcomes with Angiotensin-Converting Enzyme Inhibitors and Diuretics for Hypertension in the elderly. N Engl J Med 2003; 348(7): 583–92 Kannel WB. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 2003; 20(4): 277–86 Lewis E, Hunsicker L, Larke W, et al., for the Collaborative Study Group (IRMA2). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60 Julius S, Kjeldsen SE, Brunner H, et al. VALUE Trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003 Jul; 16(7): 544–8